Cytyc submits cervical premarket approval (PMA) supplement
This article was originally published in Clinica
Cytyc hopes to widen the appeal of its cervical cancer screening system by seeking approval for use with the most common smear collection device, the cytobrush/spatula. The ThinPrep screening system, which disperses rinsed cells onto slides for visual assessment, was approved by the US FDA in May but only for samples taken with a broom sampler (see Clinica No 707, p 18).
You may also be interested in...
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.
Skin hygiene is one of several categories where Edgewell Personal Care has a “right to win" after 18 months of renovations, according to the company’s 20 November Investor Day presentation. The firm has doubled its production capacity and has plans for a “full suite” of product innovation to build on Wet Ones’ 60% growth in fiscal 2020.
Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.